Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Agnès
A
Depatureaux
Marie
M
Leoz
Gwenae
G
Le Moal
Jean-Paul
JP
Pathé
Juliette
J
Pavie
Dominique
D
Batisse
Vincent
V
Daneluzzi
Philippe
P
Genet
Laurence
L
Gerard
Anne-Sophie
AS
Lascaux-Cametz
Tessa
T
Lambolez
Jean-Marie
JM
Chennebault
Jean-Christophe
JC
Plantier
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000145:classification* / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000008:administration & dosage*; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium